Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EpiminderASX:EPI +4.55%8 Cash Ratio is 22.80 as of Dec. 2025, which is 64% above its 10-year median of 13.92. GuruFocus rates ASX:EPI with a GF Score™ of 8/100. Among 837 Medical Devices & Instruments companies, Epiminder ranks better than 98.81% on this metric.
Epiminder has a Cash Ratio of 22.80. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Epiminder's Cash Ratio or its related term are showing as below:
ASX:EPI'
s Cash Ratio Range Over the Past 10 Years
Min: 5.04 Med: 13.92 Max: 22.8
Current: 22.8
During the past 3 years, Epiminder's highest Cash Ratio was 22.80. The lowest was 5.04. And the median was 13.92.
ASX:EPI's Cash Ratio is ranked better than 98.81% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs ASX:EPI: 22.80
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Epiminder Cash Ratio Related Terms
Epiminder Cash Ratio Historical Data
* Premium members only.
The historical data trend for Epiminder's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epiminder Cash Ratio Chart
Epiminder Annual Data
Trend
Jun23
Jun24
Jun25
Cash Ratio
0.00
0.00
5.04
Epiminder Semi-Annual Data
Jun23
Jun24
Jun25
Dec25
Cash Ratio
0.00
0.00
5.04
22.80
ASX:EPI vs ABT, SYK, MDT: Cash Ratio Comparison
For the Medical Devices subindustry, Epiminder's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epiminder Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Epiminder's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Epiminder's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epiminder (ASX:EPI) has a Cash Ratio of 22.80 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Epiminder and its competitors. This is 64% above median its historical median of 13.92. Over the past decade, Epiminder's Cash Ratio has ranged from 5.04 to 22.80. According to the industry distribution chart, Epiminder ranks #10 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 1.2%.
Is Epiminder's Cash Ratio too high?
Epiminder's current Cash Ratio of 22.80 is 64% above median its 10-year median of 13.92. Over the past 10 years, this metric has ranged from a low of 5.04 to a high of 22.80. The Medical Devices & Instruments industry median Cash Ratio is 0.95. Epiminder's value of 22.80 is 2300% above this industry median. Based on the distribution chart, Epiminder ranks #10 out of 837 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Epiminder has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Epiminder's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Epiminder ranks #10 out of 837 companies for Cash Ratio. This places Epiminder in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.95. Epiminder's value of 22.80 is 2300% above this benchmark. Historically, Epiminder's own Cash Ratio has ranged from 5.04 to 22.80 over the past decade. While the company's 10-year median is 13.92 vs. the industry median of 0.95, Epiminder has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epiminder's current Cash Ratio of 22.80 is 2300% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Epiminder and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epiminder's current Cash Ratio is 22.80, which is 64% above median its own 10-year median of 13.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epiminder stock overvalued right now?
Epiminder (ASX:EPI) has a current Cash Ratio of 22.80. The current Cash Ratio is 22.80, which is 64% above median its 10-year median of 13.92 and 2300% above the Medical Devices & Instruments industry median of 0.95. Epiminder's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Epiminder (ASX:EPI), the current Cash Ratio is 22.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Epiminder Ltd is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy. Its system is a sub-scalp device for continuous monitoring of electrographic brain activity and a set of information solutions, providing patients and their healthcare professionals with detailed data over an extended period.
8GF Score
Get the complete analysis for ASX:EPI
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPI has been successfully added to your 
